Axsome Therapeutics reports surging revenue and pipeline progress in 2024

Axsome Therapeutics has reported strong financial growth alongside key developments in its drug pipeline. The company's revenue surged by double digits, while prescription volumes for its products also rose sharply. Meanwhile, regulatory progress and commercial expansion are underway for its leading treatments.

The company's net loss shrank significantly compared to the previous year. Management confirmed that current cash reserves will support operations until cash flow turns positive under the existing plan.

Sales efforts have ramped up, with around 450 representatives now promoting Auvelity and Cymbravo globally. This expansion follows FDA approvals in 2022 and 2023, boosting U.S. commercialisation. Key launch preparations for Auvelity are already in motion, alongside improved payer access for both drugs.

Regulatory momentum continues as the FDA granted a priority review for Auvelity's supplemental New Drug Application (sNDA). The agency will decide by April 30 on its use for Alzheimer's-related agitation. Beyond this, Axsome is advancing multiple Phase III trials and regulatory filings across its pipeline.

The company has also broadened its focus by adding AXS-17, a new candidate for epilepsy treatment. Existing products like Sunosi have maintained steady growth, further strengthening Axsome's market position.

Axsome Therapeutics now has a larger sales team, stronger revenue, and a streamlined regulatory path for Auvelity. The upcoming FDA decision and ongoing trials could expand its treatment options. With cash reserves secured, the company is positioned to sustain operations while pursuing further growth.